The medical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s showing significant efficacy in clinical trials for treating obesity. Unlike some available weight loss treatments, retatrutide appears to offer a more substantial decrease in